Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q3 FY20 Earnings Presentation
24 slides from Dishman Carbogen Amcis's earnings presentation, Jan 24, 2020
Slide 1: Cover letter to stock exchanges
.24th January, 2020 dishman To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, "Exchange Plaza", C-1, Block G, Mumbai - 400 001. Bandra-Kurla Complex, Sandra (E), Mumbai - 400 051. Ref.: Sc
Slide 2: Q3 & 9M FY20 Results Update
DISHMAN CARBOGEN AMCIS LIMITED Q3 & 9M FY20 RESULTS UPDATE JANUARY 2020 1
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward looking statements, which may include statements relating to future results of
Slide 4: Discussion Summary
DISCUSSION SUMMARY ❖ Q3 FY20 RESULTS UPDATE ❖ INDUSTRY OVERVIEW ❖ COMPANY OVERVIEW 3
Slide 5: Q3 & 9M FY20 Results Update
Q3 & 9M FY20 RESULTS UPDATE 4
Slide 6: Q3 FY20 Result Highlights
Q3 FY20 RESULT HIGHLIGHTS In Rs Mn REVENUES EBITDA & EBITDA MARGIN * 5,423 27.7% 4,789 23.1% 1,327 1,254 13.2% Q3 FY19 Q3 FY20 Q3 FY19 Q3 FY20 ADJUSTED PBT # & PBT MARGIN CASH PAT @ & CASH EPS 20.2% 6.5 13.4% 6.4 966 1,032 1,009 728 Q3 FY19 Q3 FY20 Q3 FY19 Q3 FY20 @ Cash PAT = Adjusted PAT + (Deprec
Slide 7: 9M FY20 Result Highlights
9M FY20 RESULT HIGHLIGHTS In Rs Mn REVENUES EBITDA & EBITDA MARGIN * 15,315 14,089 27.2% 25.5% 3,825 3,906 7.9% 9M FY19 9M FY20 9M FY19 9M FY20 ADJUSTED PBT # & PBT MARGIN CASH PAT @ & CASH EPS 20.7% 16.4% 20.9 20.2 2,918 3,378 3,265 2,507 9M FY19 9M FY20 9M FY19 9M FY20 @ Cash PAT = Adjusted PAT +
Slide 8: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (In Rs. Mn.) Q3 FY20 Q3 FY19 YoY % 9M FY20 9M FY19 YoY % Revenue from Operations 5,193.6 4,273.9 21.5% 14,704.4 13,085.2 12.4% Other Operating Income 229.2 515.5 -55.5% 610.5 1,003.6 -39.2% Total Revenues 5,422.8 4,789.4 13.2% 15,314.9 14,088.8 8.7% COGS 1,296.
Slide 9: Q3 & 9M FY20 Segment-wise Revenue Analysis
Q3 & 9M FY20 SEGMENT-WISE REVENUE ANALYSIS In Rs Mn Revenues – Segment wise Breakup Q3 FY20 Q3 FY19 YoY% 9M FY20 9M FY19 YoY% CRAMS (% of total) 77.5% 78.1% 76.5% 76.3% CRAMS – India 513.8 765.0 -32.8% 2,406.9 2,100.8 14.6% CRAMS – CAAG+RIOM* 3313.5 2,368.4 39.9% 8,032.1 7,265.0 10.6% CRAMS – UK 196
Slide 10: Segment-wise Revenue Break-up
SEGMENT-WISE REVENUE BREAK-UP Total Operating Revenue – Q3 FY20 Total Operating Revenue – 9M FY20 CRAMS – 77.5% Marketable Molecules – 22.5% CRAMS – 76.5% Marketable Molecules – 23.5% 5% 7% 54% 49% 51% 100% 71% 100% 82% 46% 21% 13% CRAMS - India CRAMS - CAAG+RIOM* CRAMS - UK CRAMS - India CRAMS - CA
Slide 11: Q3 & 9M FY20 Segment-wise Margin Analysis
Q3 & 9M FY20 SEGMENT-WISE MARGIN ANALYSIS EBITDA Margin % – Segment wise Q3 FY20 Q3 FY19 9M FY20 9M FY19 CRAMS CRAMS – India 54.0% 59.6% 56.3% 58.3% CRAMS – CAAG+RIOM* 21.5% 20.3% 20.3% 20.4% CRAMS – UK 13.9% 32.0% 16.8% 26.1% Marketable Molecules Carbogen Amcis BV** 31.1% 41.4% 33.8% 42.7% Others#
Slide 12: Q3 & 9M FY20 Result Highlights
Q3 & 9M FY20 RESULT HIGHLIGHTS Financial Highlights: ❑ Total Revenues increased by 13.2% YoY to Rs 5,422.8 mn in Q3 FY 2020. ❖ CRAMS revenue grew by 20.5% YoY primarily due to : ❖ CRAMS Carbogen Amcis AG revenue increased by 39.9 %, attributable to scheduled delivery of orders built up in Q2 ❖ CRAMS
Slide 13: Company Overview
COMPANY OVERVIEW 12
Slide 14: Brief Profile
BRIEF PROFILE BUSINESS OVERVIEW KEY STRENGTHS FINANCIAL OVERVIEW • Integrated CRAMS company with strong • Preferred global outsourcing partner with • Consolidated Revenues, EBITDA and capabilities right from process research & capabilities across the entire CRAMS value Adj. PAT of Rs 20,586 Mn, Rs 5
Slide 15: Manufacturing Facilities – Robust R&D Capabilities
MANUFACTURING FACILITES – ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, TGA, WHO, KFDA Superior Chemistry Skills & Capabilities • 28 dedicated R&D labs with multiple-shift R&D operations, including HIPO labs • 25 multi-purpose facilitie
Slide 16: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER INTEGRATED STRONG CLOSE PROXIMITY LARGE SCALE ACROSS THE VALUE CHEMISTRY TO CLIENTS WITH MANUFACTURING CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 17: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER Integrated CRAMS Player – Strong Capabilities across the Value Chain Carbogen Amcis (CA) Strong Research Capabilities EARLY STAGE LATE STAGE COMMERCIAL SUPPLY • Focus is on supporting the Process research and API supply to Process development and Secure, value-for-money devel
Slide 18: Cutting-Edge HIPO Capabilities
CUTTING-EDGE HIPO CAPABILITIES World Class HIPO capabilities • Facilities range from laboratory scale for process research and development to large scale manufacturing on 8,000 L scale, with an ability to handle the highest category IV compounds (high toxicity levels). • State-of-the-art containment
Slide 19: Corporate Restructuring
CORPORATE RESTRUCTURING SCHEME OF ARRANGEMENT & AMALGAMATION IMPACT OF MERGER • The amalgamation has been accounted under the "Purchase Method" as per • The Board Of Directors approved the Scheme of Arrangement and AS14. Amalgamation on 24th February 2016, which involves merger of Dishman • Accordin
Slide 20: Industry Overview
INDUSTRY OVERVIEW 19
Slide 21: Global Spending on Medicine
GLOBAL SPENDING ON MEDICINE As per BRC Report, Contract Research Outsourcing (CRO) Market to reach $44.4bn by 2021 • Oncology is expected to be the most critical therapeutic segment driving the global spend on medicine in future. Outlook of Leading Therapy Areas Spending and Growth, Constant US $ Bn
Slide 22: Global Medicines in Late Stage Development
GLOBAL MEDICINES IN LATE STAGE DEVELOPMENT Oncology 29% • Oncology has become one of the major focus 13% areas for pharmaceutical and biotechnology companies. CNS 11% 7% • Around 29% of the Phase II / III clinical trials are in the Oncology segment. Anti-Infectives / 6% Antivirals 9% • Oncology (can
Slide 23: Global Oncology Medicine Pipeline
GLOBAL ONCOLOGY MEDICINE PIPELINE ➢ 710 Molecules in late-stage development and 700+ companies with late-stage oncology drugs. ➢ Top companies with combined sales of $10bn+ have ~40% of their product pipeline in oncology. ➢ 455 smaller companies with 90%+ product pipeline in oncology, are involved i
Slide 24: For Further Queries
FOR FURTHER QUERIES: Mr. Harshil Dalal Group CFO Email: harshil.dalal@dishmangroup.com Mr. Nachiket Kale / Chintan Mehta IR Consultants Contact: +91 9920940808 / +91 9892183389 Email:dishman@dickensonworld.com 23
Dishman Carbogen Amcis — Q3 FY20 Earnings Presentation on 6ix